Acrivon Therapeutics

NMQ:ACRV · US0048901096

BiotechnologySmall

360° View

Value43

Price/Sales50

Price/Earnings1

Price/Book63

Dividend Yield—

Growth24

Revenue Growth—

Profit Growth63

Capital Growth13

TSR 52w18

Safety20

Leverage49

Liquidity67

Refinancing1

Combined14

Sentiment35

Analyst Opinions27

Pro Holdings33

Opinion Changes50

Market Pulse59

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Founded2018

Employees76

Websiteacrivon.com

ISINUS0048901096

Last UpdateApr 2, 2026

Index & Theme

Health DiagnosticsImmunologyInflammationGeneticsOncologyBiotechnologyHealth CareTherapeutics

Description

Acrivon Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is discovering and developing precision oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing the compa…

Analysis

Acrivon Therapeutics's 360° View rank of 6 places it among the weakest overall — better than 6% of its true peers.

It's lagging on growth (24) and on the expensive side (43). On safety it is highly leveraged (20), and the market shows muted sentiment (35). Taken together, its Combined rank of 14 reads as among the weakest overall.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Acrivon Therapeutics with its peers

BridgeBio Oncology Therapeutics

NMQ:BBOT

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Celcuity

NAQ:CELC

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Repare Therapeutics

NSQ:NULL

—

CountryCanada

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Immuneering

NMQ:IMRX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Syndax Pharmaceuticals

NSQ:SNDX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Biomea Fusion

NSQ:BMEA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →